| INTRODUCTION
Patients with end-stage renal disease requiring haemodialysis are at high risk of hepatitis C virus (HCV) infection; the reported prevalence ranges from 1% to 75%.
1,2 Acute HCV infection is the period within 6 months of infection. An epidemic of acute hepatitis C (AHC) has been observed in patients with end-stage renal disease. 3 In the USA, the estimated incidence of new cases of hepatitis C is approximately 38 000 per year, and the prevalence of HCV infection in the haemodialysis population is 10-fold higher than that in the general population. 4 Unfortunately, there are a lack of data pertaining to the treatment of acute hepatitis in patients with end-stage renal disease requiring haemodialysis. Historically, the treatment of AHC with interferon is effective; however, it has been associated with frequent side-effects, intolerance, and relatively lower sustained virological response (SVR) compared with interferon-free regimens. [5] [6] [7] Most patients with end-stage renal disease also have conditions that contraindicate interferon therapy, such as chronic kidney diseases (CKDs), coronary or cerebrovascular diseases, poorly controlled diabetes and neuropsychiatric diseases. The options for these patients are limited.
The treatment of chronic HCV has been revolutionised by the advent of directly acting antiviral (DAAs). 8 The approval of several novel DAAs drugs against HCV has allowed for interferon-free therapy of chronic hepatitis C. However, there are limited data on the treatment of acute HCV infection. Liu et al have reported a case of overlap syndrome in acute HCV infection (through blood transfusion) that was treated with sofosbuvir and ribavirin for 12 weeks. 9 Millard et al reported four cases of AHC in HIV-infected men who have sex with men; these patients were treated with Harvoni (400 mg sofosbuvir plus 90 mg ledipasvir), once per day, for 8-12 weeks. 10 To date, only one small study has been conducted investigating DAAs treatment for AHC. Deterding et al have described the safety and efficacy of a 6-week treatment of AHC with Ledipasvir (90 mg) plus sofosbuvir (400 mg). 11 Their observations supported the treatment of AHC with DAAs, however, none of these studies focused on patients with end-stage renal disease requiring haemodialysis, who are at high risk of HCV infection. Moreover, the safety of DAAs in these patients remained unknown. An early study showed that telaprevir-based treatment resulted in decreased renal function.
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Among the currently approved DAAs, sofosbuvir, the cornerstone of most anti-HCV regimens, predominantly undergoes renal elimination. 13, 14 However, recommendations regarding sofosbuvir-based regimens for AHC in haemodialysis patients lack label information, as well as guidelines from the American Association for the Study of Liver Diseases (AASLD), 15 the European Association for the Study of the Liver (EASL), 16 the Asian Pacific Association for the Study of the Liver, and the National Kidney Foundation. 17 In January 2016, an epidemic nosocomial outbreak of HCV infection in two blood purification centres was traced to a single source of exposure in central China. During the process of public health control, most patients requested directly acting antivirals. Here, we report on the efficacy and safety of sofosbuvir and daclatasvir in treating acute HCV infection in patients with end-stage renal disease who are undergoing haemodialysis.
| METHODS
In January 2016, routine testing revealed ALT elevations in six patients undergoing haemodialysis at one blood purification centre in Zhen'An County, Shaanxi province, in the middle-west of China.
The area has two centres and occasionally patients were moved from one centre to another. All patients and their close household contacts, as well as the medical staff at the two centres, were tested for HCV infection. An outbreak of HCV infection was identified; all cases were acute HCV infection because the HCV antibody and liver enzyme levels were normal 3 months prior. Initially, the local government and hospital administration provided interferon/ribavirin treatment. Most acutely infected patients requested directly acting antiviral treatment because of intolerances and contraindications.
At the two blood purification centres, most renal failure patients were undergoing haemodialysis. Patients with acute renal failure and acute alcohol intoxication were also treated at the centres. We The study was performed in accordance with the Declaration of Helsinki (1996 revision) and other applicable national legislation.
| Statistical analysis
All baseline data (demographic and characteristics) and end point data were summarised with descriptive statistics: medians (range, IQR), mean/SD, or N (%). ANOVA was used to compare the continuous variable (i.e. laboratory values). Values of P < .05 were considered to be statically significant. All analyses were performed using SPSS (version 18.0, Chacago, SPSS INc.), and graphs were plotted with Origin (version 8.0).
| RESULTS

| Population characteristics
A total of 47 patients with HCV infections were identified at the two blood purification centres. We enrolled 33 acute HCV-infected patients with end-stage renal disease requiring haemodialysis ( Figure 1 and Table S1 . The haemodialysis duration ranged from 8 months to 9 years. Eighteen (54.5%) patients had elevated ALT levels (above the ULN), and in three of these patients, the value was more than five times the upper limit of normal; all other patients had normal
ALT. The median HCV RNA viral load at baseline in all patients was The following patients did not achieve undetectable HCV RNA at week 4: #5, #9, #22, #25, #27 and #31 ( Figure 2 and 
| Safety outcomes
All patients completed anti-viral treatment and 12 weeks of followup. The treatment of AHC in patients with end-stage renal disease was well tolerated. A total of 52 possible drug-related AE were reported until follow-up week 12, however, none of these events were severe AEs (Table S2 and Table 2 ). The most frequently reported AEs were nausea, fatigue, anorexia, constipation and dizziness. . 20 In this study, we observed the efficacy of treatment with a reduced dose of sofosbuvir (200 mg) and a full dose of daclatasvir in patients with end-stage renal disease who were undergoing haemodialysis.
T A B L E 1 Baseline characteristics
First, we questioned whether a half dose of sofosbuvir in endstage renal disease patients is effective. Given the similarity between our study and the Katja study, 11 we compared the efficacy of half 
F I G U R E 3 Biochemical response to anti-viral treatment A rapid biochemical response was observed. Before the DAA treatment, 18 (54%) patients had elevated ALT levels; after 4 weeks of therapy, the ALT levels were reduced to normal ranges in 17 (94%) of the 18 patients All drug-related adverse events were possibly or most likely related to the study treatment, none were definitely related.
undergoing haemodialysis. Similarly, a small study of 10 GT1 HCVinfected patients with creatinine clearance <30 mL/minutes and using sofosbuvir 200 mg daily showed low efficacy (SVR 40%). 21 The ideal treatment duration for AHC with interferon-free regimens remains unknown. A short treatment duration with a full dose of sofosbuvir was highly effective in patients with acute HCV infection. 11 Katja et al have described a short duration treatment (6 weeks with a full dose of sofosbuvir plus ledipasvir) that was effective in patients with acute HCV genotype 1 monoinfection. Our study has some limitations. First, all patients enrolled in this study were victims of a nosocomial infection; although most patients had acute HCV infections, one or two patients who were the source of infection might have chronic infections. The biopsy results were not available for all patients. Second, our study design lacked a formal control group because a randomised study was considered to be unfeasible when dealing with this public health issue.
In conclusion, we present our successful experience of using a half dose of sofosbuvir and a full dose of daclatasvir to treat acute HCV infection in end-stage renal disease patients requiring haemodialysis. Anti-viral treatment with sofosbuvir-based regimens showed excellent SVR outcomes, with favourable safety and tolerability.
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